+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nutrition Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • PDF Icon

    Report

  • 140 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292926
The nutrition therapy market size was valued at USD 55.65 billion in 2025 and is estimated to grow from USD 59.29 billion in 2026 to reach USD 80.74 billion by 2031, at a CAGR of 6.40% during the forecast period (2026-2031). This report is Segmented by Product (Oral Nutritional Supplements, and More), Nutrition Type (Standard, Specialized, Disease-Specific, and More), Age Group (Neonates, Infants, and Mores), End User (Hospitals, Homecare, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Nutrition Therapy Market Trends and Insights

Aging-Linked Malnutrition and Sarcopenia Management

Population aging remains a sustained demand driver for the nutrition therapy market. The 2025 Asian Working Group for Sarcopenia consensus expanded sarcopenia diagnostic criteria to include adults aged 50 to 64 years, broadening eligibility for oral nutritional supplements and high-protein medical foods. Japan’s 2025 guidance recommended protein intake of 1.2 to 1.5 g/kg/day for older adults with disease-related malnutrition, supporting demand for high-protein enteral products. A 2025 network meta-analysis found that resistance training combined with nutritional supplementation delivered better sarcopenia outcomes than either intervention alone. This evidence supports nutrition care before and after hospitalization and expands dispensing opportunities across homecare and retail settings.

Rising Chronic Disease and Oncology Nutrition Demand

Chronic disease and oncology care are increasing the need for systematic nutrition assessment and treatment in the nutrition therapy market. Cancer-related malnutrition affects 30% to 85% of oncology patients, while nutrition support protocols remain inconsistently integrated across care pathways. The Crohn’s & Colitis Foundation stated in its 2025 white paper that exclusive enteral nutrition is a first-line option for inducing remission in Crohn’s disease, with pediatric remission rates of 67% to 80%.

A 2025 cohort study reported that infliximab combined with partial enteral nutrition improved the 14-week clinical response rate to 87.01%, compared with 74.75% for monotherapy, and the 54-week endoscopic remission rate to 84.42%, compared with 65.66%. Danone’s 2026 partnership with the Union for International Cancer Control shows that nutrition advocacy is becoming part of commercial efforts to improve access to oncology care. ESPEN’s 2025 guidance also incorporated nutrition risk assessment from pre-admission through post-discharge, embedding nutrition care within the broader clinical pathway.

Uneven Reimbursement for Oral and Home Enteral Nutrition

Reimbursement gaps for oral nutritional supplements and home enteral nutrition restrict patient access despite clear clinical need. National Home Infusion Association analysis of CMS data showed that Medicare home enteral nutrition kit suppliers declined by 31%, while beneficiaries receiving home enteral nutrition fell by 27% between 2014 and 2023. The supplied data also showed that the average cost of preparing a home parenteral nutrition bag increased by 75.4% from 2016 through 2024, while average service reimbursement declined from 2022 to 2024. These cost and reimbursement pressures challenge the operational viability of smaller specialized providers. Delayed access to clinically indicated nutrition products can postpone treatment until hospitalization becomes unavoidable.

Other drivers and restraints analyzed in the report include:
  • GLP-1-Associated Muscle Loss and Nutritional Support Demand
  • Shift from Hospital to Home-Based Nutrition Support
  • High Clinical-Grade Manufacturing and Compliance Costs

Segment Analysis

Oral nutritional supplements held 45.66% of the nutrition therapy market share in 2025 and are projected to grow at an 8.56% CAGR from 2026 to 2031. They support disease-related malnutrition, oncology, surgical recovery, hospital care, and ambulatory treatment. Tube-fed enteral nutrition remains important in intensive care, oncology, and neurological care, while parenteral nutrition serves patients with complex clinical needs. A 2025 review reported that polymeric enteral formulas achieved remission induction in up to 85% of pediatric Crohn’s disease cases.

Baxter’s 2025 and 2026 patent activity for terminally heat-sterilized multichamber parenteral nutrition bags focused on simplifying bedside preparation and reducing dosing errors. Danone’s July 2025 acquisition of a majority stake in Kate Farms combined Kate Farms, Nutricia, Real Food Blends, and Functional Formularies within a North American medical nutrition platform. The platform is eligible for Medicare, Medicaid, and WIC coverage in 35 states and is present in more than 1,500 U.S. hospitals. Fresenius Kabi launched NutriChef in September 2026 across six European markets, with ingredients from 21 plants and more than 75% real-food content.

Standard nutrition commanded 38.45% of demand in 2025, supported by its broad use in hospital formularies for general calorie and macronutrient requirements. Disease-specific nutrition is forecast to grow at a 9.73% CAGR from 2026 to 2031. These formulas address renal disease, liver disease, cancer, and malabsorption through targeted amino acid, protein, and micronutrient profiles. Elemental and semi-elemental formulas support patients with inflammatory bowel disease and malabsorption who cannot tolerate intact proteins.

The 2025 ECCO consensus recommended polymeric formulas as the preferred enteral option for inflammatory bowel disease due to comparable efficacy and better palatability. Modular nutrition is increasingly used for protein augmentation in GLP-1 care protocols. Medical foods for inborn errors of metabolism require controlled manufacturing and regulatory compliance, while payers increasingly seek therapeutic-outcome evidence for reimbursement. Danone opened its OneBiome Lab in Paris-Saclay in 2025 to combine microbiology and clinical nutrition research.

Complete Report Scope:

  • By Product and Route of Administration
    • Oral Nutritional Supplements
    • Tube-Fed Enteral Nutrition
    • Parenteral Nutrition
    • Others
  • By Nutrition Type
    • Standard Nutrition
    • Specialized Nutrition
    • Disease-Specific Nutrition
    • Elemental and Semi-Elemental Nutrition
    • Modular Nutrition
    • Medical Foods for Inborn Errors of Metabolism
  • By Therapeutic Area
    • Malnutrition and Disease-Related Malnutrition
    • Oncology
    • Diabetes
    • Gastrointestinal Diseases
    • Neurological Diseases
    • Renal Diseases
    • Respiratory Diseases
    • Cardiovascular Diseases
    • Liver Diseases
    • Others
  • By Age Group
    • Neonates
    • Infants
    • Children
    • Adults
    • Older Adults
  • By End User
    • Hospitals and Ambulatory Surgical Centers
    • Homecare Settings
    • Nursing Homes and Senior Homes
    • Specialty Clinics
    • Rehabilitation Centers
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-Commerce
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 41.78% of the nutrition therapy market share in 2025, supported by established hospital infrastructure and medical food oversight. The region has a strong demand for hospital- and home-based clinical nutrition. National Home Infusion Association data show that home parenteral nutrition bag preparation costs increased by 75.4% from 2016 to 2024, while Medicare home enteral nutrition suppliers declined by 31% from 2014 to 2023. These constraints affect provider capacity despite rising patient needs. The Healthcare Nutrition Council’s 2026 support for H.R. 2172 and the CMS memorandum cited in the supplied research indicate greater policy focus on improving access.

Asia-Pacific is forecast to grow at a CAGR of 8.59% from 2026 to 2031, driven by aging populations and expanding insurance coverage for clinical nutrition in China, Japan, and South Korea. In its November 2025 presentation, Fresenius Kabi identified itself as the leading parenteral nutrition supplier in China. Japan’s 2025 guidelines provide specific nutritional management standards for sarcopenia and frailty. The 2025 AWGS consensus broadened the age range for sarcopenia screening, potentially expanding the eligible patient population in South Korea, Australia, and India. Europe has established nutrition protocols in Germany, France, and the United Kingdom, where disease-specific formulas and homecare models are key competitive areas. ESPEN’s 2025 surgical and geriatric guidelines support nutrition interventions across a broader patient population.

GCC health strategies increasingly position clinical nutrition within noncommunicable disease management, supporting structured market entry across the Middle East and Africa. In South America, Brazil leads the market, with the SUS public health system continuing to expand enteral nutrition coverage, according to the supplied research. Argentina relies more heavily on private healthcare networks as the primary distribution channel. These regional differences require suppliers to tailor reimbursement, registration, and distribution strategies to each healthcare system.


List of Companies Covered in this Report:

  • Abbott Laboratories
  • Ajinomoto Co., Inc.
  • AYMES International Limited
  • B. Braun
  • Baxter
  • Danone
  • Fresenius
  • Functional Formularies, LLC
  • Hormel Foods
  • Kate Farms, Inc.
  • Medtrition, Inc.
  • Meiji Holdings Co., Ltd.
  • Nestle S.A.
  • Nutrisens SAS
  • Perrigo Company
  • Primus Pharmaceuticals, Inc.
  • Real Food Blends, LLC
  • Reckitt Benckiser Group
  • Smartfish AS
  • Vegenat S.A.
  • Vitaflo International Limited

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging-Linked Malnutrition and Sarcopenia Management
4.2.2 Rising Chronic Disease and Oncology Nutrition Demand
4.2.3 Shift from Hospital to Home-Based Nutrition Support
4.2.4 Mainstreaming of Evidence-Based Nutrition Care
4.2.5 GLP-1-Associated Muscle Loss and Nutritional Support Demand
4.2.6 Formula Personalization Through Disease, Tolerance, and Microbiome Data
4.3 Market Restraints
4.3.1 Uneven Reimbursement for Oral and Home Enteral Nutrition
4.3.2 High Clinical-Grade Manufacturing and Compliance Costs
4.3.3 Fragmented Product Classification Across Food, Medical Food, and Drug Rules
4.3.4 Limited Interoperability Between Nutrition Data and Clinical Workflows
4.4 Supply/Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers Analysis
4.7.2 Bargaining Power of Buyers Analysis
4.7.3 Threat of New Entrants Analysis
4.7.4 Threat of Substitutes Analysis
4.7.5 Competitive Rivalry Analysis
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Product and Route of Administration
5.1.1 Oral Nutritional Supplements
5.1.2 Tube-Fed Enteral Nutrition
5.1.3 Parenteral Nutrition
5.1.4 Others
5.2 By Nutrition Type
5.2.1 Standard Nutrition
5.2.2 Specialized Nutrition
5.2.3 Disease-Specific Nutrition
5.2.4 Elemental and Semi-Elemental Nutrition
5.2.5 Modular Nutrition
5.2.6 Medical Foods for Inborn Errors of Metabolism
5.3 By Therapeutic Area
5.3.1 Malnutrition and Disease-Related Malnutrition
5.3.2 Oncology
5.3.3 Diabetes
5.3.4 Gastrointestinal Diseases
5.3.5 Neurological Diseases
5.3.6 Renal Diseases
5.3.7 Respiratory Diseases
5.3.8 Cardiovascular Diseases
5.3.9 Liver Diseases
5.3.10 Others
5.4 By Age Group
5.4.1 Neonates
5.4.2 Infants
5.4.3 Children
5.4.4 Adults
5.4.5 Older Adults
5.5 By End User
5.5.1 Hospitals and Ambulatory Surgical Centers
5.5.2 Homecare Settings
5.5.3 Nursing Homes and Senior Homes
5.5.4 Specialty Clinics
5.5.5 Rehabilitation Centers
5.5.6 Others
5.6 By Distribution Channel
5.6.1 Hospital Pharmacies
5.6.2 Retail Pharmacies
5.6.3 E-Commerce
5.6.4 Others
5.7 By Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 India
5.7.3.3 Japan
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Ajinomoto Co., Inc.
6.3.3 AYMES International Limited
6.3.4 B. Braun SE
6.3.5 Baxter International Inc.
6.3.6 Danone S.A.
6.3.7 Fresenius Kabi AG
6.3.8 Functional Formularies, LLC
6.3.9 Hormel Foods Corporation
6.3.10 Kate Farms, Inc.
6.3.11 Medtrition, Inc.
6.3.12 Meiji Holdings Co., Ltd.
6.3.13 Nestle S.A.
6.3.14 Nutrisens SAS
6.3.15 Perrigo Company plc
6.3.16 Primus Pharmaceuticals, Inc.
6.3.17 Real Food Blends, LLC
6.3.18 Reckitt Benckiser Group plc
6.3.19 Smartfish AS
6.3.20 Vegenat S.A.
6.3.21 Vitaflo International Limited
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Ajinomoto Co., Inc.
  • AYMES International Limited
  • B. Braun SE
  • Baxter International Inc.
  • Danone S.A.
  • Fresenius Kabi AG
  • Functional Formularies, LLC
  • Hormel Foods Corporation
  • Kate Farms, Inc.
  • Medtrition, Inc.
  • Meiji Holdings Co., Ltd.
  • Nestle S.A.
  • Nutrisens SAS
  • Perrigo Company plc
  • Primus Pharmaceuticals, Inc.
  • Real Food Blends, LLC
  • Reckitt Benckiser Group plc
  • Smartfish AS
  • Vegenat S.A.
  • Vitaflo International Limited